Home › NDC Lookup › Ingredients › Baclofen › 70756-0085-11
Baclofen 5 mg Tablet, 100-count — NDC 70756-0085-11 package photo
Label image from the product's FDA listing (DailyMed) — may show a different pack size or an older label revision.

Baclofen 5 mg Tablet, 100-count — NDC 70756-085-11 (Billing 70756-0085-11)

by Lifestar Pharma LLC · 100 TABLET in 1 BOTTLE

This is a package of 100 tablets of Baclofen 5 mg Tablet from Lifestar Pharma LLC, marketed since Jan 2022 and currently FDA-listed; retail pharmacies pay about $0.0680 per tablet (NADAC). It is this product's only package size.

NDC 70756-0085-11
🏷️ FDA NDC (as labeled) 70756-085-11 billing pads the product segment with a zero
Rx only Generic On market Non-controlled ⇄ Compare with another NDC
🗂️ FDA directory synced Oct 1, 2026 · this listing last changed Jul 24, 2026 · sources: openFDA · FDA label (DailyMed) · FDA Orange & Purple Book · First Databank · CMS NADAC, ASP, Medicare & Medicaid · RxNorm
📋 All sources & update times →
⚠️
Other active recalls for Baclofen (different manufacturers) — 1 · tap to view
These affect other manufacturers’ products for the same ingredient — not necessarily the exact NDC on this page.
Class II · Nov 26, 2025 — Presence of Foreign Tablets/Capsules (Golden State Medical Supply Inc.) · FDA recall D-0235-2026
Each entry is an official FDA enforcement report — look up any recall number in the FDA recall database ↗

Identity & classification

Regulatory identifiers FDA, NLM and CMS codes for this package

FDA NDC (as labeled) 70756-085-11
Product NDC 70756-085
11-digit billing NDC 70756008511
NCPDP billing unit EA — each (per item)
RxCUI 197391, 197392, 430902
UNII H789N3FKE8
UPC 0370756288121, 0370756289517, 0370756288114, 0370756288992 +1 more
Application # ANDA215885
SPL Set ID f9dd1b55-2984-446a-8146-2ab0f5211e15
Established class (EPC) gamma-Aminobutyric Acid-ergic Agonist
Mechanism of action GABA A Agonists; GABA B Agonists
DEA schedule Non-controlled
Marketing category ANDA
Marketing status On market
FDA listing status Listed (active directory)
Marketing start 2022-01-26
Route ORAL
Dosage form TABLET
Substance BACLOFEN
TE code (Orange Book) AB · RLD · RS

Drug-database identifiers Medi-Span GPI and First Databank GCN / HICL / AHFS classification

GPI-14 75100010000303
GPI class Baclofen
GCN Seq No 027229
GCN 18012
HICL code 001949
Ingredient (HICL) Baclofen
HIC1 code H
Therapeutic class — broad (HIC1) Nervous System (Except Autonomic)
HIC2 code H6
Therapeutic class — intermediate (HIC2) Drugs Acting Principally On The Midbrain
HIC3 code H6H
Therapeutic class — specific (HIC3) Skeletal Muscle Relaxants
AHFS code 12:20.12.00
AHFS class Gaba-Derivative Skeletal Muscle Relaxant
FDB label name BACLOFEN 5 MG TABLET
FDB brand name Baclofen
Legend status F — Federal legend — prescription drug or device
Quick answers
  • GSN (GCN sequence number): 027229
  • GCN: 18012
  • GPI-14 (Medi-Span): 75100010000303
  • HICL (First Databank): 001949
  • AHFS class code: 12:20.12.00
  • RxCUI (RxNorm): 197391
Why two NDCs? The FDA registers this code as 70756-085-11 — a 5-3-2 layout, and that's what's printed on the package and shown on DailyMed. For insurance claims, every NDC is standardized to a uniform 11-digit 5-4-2 format by adding a zero to the product segment → 70756-0085-11. Same drug, same package — only the format differs.
Where does this data come from?
Identifiers from the FDA openFDA NDC Directory and Structured Product Labeling; RxCUI from RxNorm (NLM); GPI from Medi-Span; GCN / HIC / AHFS / legend from First Databank.

RxNorm drug class

This medicine belongs to the gamma-Aminobutyric Acid-ergic Agonist class.

Pharmacologic class gamma-Aminobutyric Acid-ergic Agonist
Drug family (ATC) Other centrally acting agents
How it works GABA B Agonists, GABA A Agonists
Where does this data come from?
Therapeutic classes from RxNorm RxClass (U.S. National Library of Medicine) — Established Pharmacologic Class (FDA), ATC drug family (WHO) and mechanism of action, matched by this product’s RxCUI.

Clinical

Label name BACLOFEN 5 MG TABLET Ingredient Baclofen
📖 What it is MedlinePlus · NLM

Baclofen is used to treat pain and certain types of spasticity (muscle stiffness and tightness) from multiple sclerosis, spinal cord injuries, or other spinal cord diseases. Baclofen is in a class of medications called skeletal muscle relaxants. Baclofen acts on the spinal cord nerves and decreases the number and severity of muscle spasms caused by multiple sclerosis or spinal cord conditions. It also relieves pain and improves muscle movement.

Read the full MedlinePlus article ↗
📗 Our plain-language guide HelloPharmacist
  • It eases spasticity, meaning stiff, tight muscles and spasms. Oral forms are used mainly for spasticity from multiple sclerosis and may help with spinal cord injuries. Intrathecal...
  • Oral baclofen is usually started low and split into several doses a day, then increased slowly. Follow your prescriber and label. With liquids, double-check both the mg and mL on y...
  • Don't stop suddenly. Your dose should be lowered slowly. With an intrathecal pump, missing a refill can cause dangerous withdrawal, so keep every appointment.
  • Sleepiness, dizziness, nausea, headache, low blood pressure and muscle weakness are common. Avoid driving until you know how it affects you, and avoid alcohol.
📖 Read our full Baclofen guide →
Where does this data come from?
Plain-language summary from MedlinePlus (U.S. National Library of Medicine); supplement & herbal interactions and nutrient depletion data from the Natural Medicines database; our full guide is HelloPharmacist editorial content.

Pricing

A drug doesn't have one price. Each row is a different public payment system, and none is what you'd pay at the counter — that depends on your insurance. The ⓘ on each row explains what it measures.

Price systemPer eaPer package
Retail pharmacies payNADAC · weekly $0.068 $6.80 / 100 tablets
Medicaid paysCMS SDUD · 12 mo $0.2298 $22.98 / 100 tablets
Medicare drug plans payPart D · Q2 2026 $0.1147 $11.47 / 100 tablets
NADAC price history (per ea) — tap or hover for the price & month
Sep 2022 Feb 2024 Apr 2026 Sep 2026 $0.397 $0.063
▼ Down 83% over the last 16 months.
Where does this data come from?
NADAC (National Average Drug Acquisition Cost) is the CMS weekly pharmacy-acquisition-cost survey — what pharmacies pay. ASP (Average Sales Price) is the CMS Medicare Part B drug-payment file, published quarterly. Medicaid pays is computed by us from CMS State Drug Utilization Data (total reimbursed ÷ units, trailing 12 months) — gross of rebates and inclusive of dispensing fees, so it reflects what Medicaid paid, not an acquisition cost. Medicare drug plans pay is the median negotiated point-of-sale unit cost across plans listing this NDC in the CMS quarterly Prescription Drug Plan pricing files, before rebates. The VA pays is the federal contract price (FSS, and the statutory Big 4 ceiling where listed) from the VA National Acquisition Center pharmaceutical price file. All are free public government data; each measures a different payer, so the figures are not directly comparable.

Packaging — all sizes for this product

Package NDCDescription Marketing startMarketing endStatus
70756-0085-11 You're viewing this Main listing 100 TABLET in 1 BOTTLE 2022-01-26 — Active

Therapeutic equivalents

ProductLabelerPackNADAC/unitTEStatusPrice vs. this
Baclofen 5 mg 00527-1333-01 Lannett 100 tablets $0.068 AB Availability likely —
Baclofen 5 mg 00904-7558-06 Major 50 tablets $0.068 AB Availability likely —
Baclofen 5 mg 16571-0169-01 Rising 100 tablets $0.068 AB Availability likely —
Baclofen 5 mg 29300-0474-01 Unichem 100 tablets $0.068 AB Availability likely —
Baclofen 5 mg 50268-0105-15 AvPAK 50 tablets $0.068 AB Availability likely —
Baclofen 5 mg 52817-0319-10 TruPharma 100 tablets $0.068 AB Availability likely —
Baclofen 5 mg 58657-0730-01 Method 100 tablets $0.068 AB Availability likely —
Baclofen 5 mg 58657-0930-01 Method 100 tablets $0.068 AB Availability likely —
Baclofen 5 mg 60687-0804-65 American 50 tablets $0.068 AB Availability likely —
Baclofen 5 mg 62135-0472-90 Chartwell 90 tablets $0.068 AB Availability likely —
Baclofen 5 mg 70710-1609-01 Zydus 100 tablets $0.068 AB Availability likely —
Baclofen 5 mgthis 70756-0085-11 Lifestar 100 tablets $0.068 AB Availability likely —
Baclofen 5 mg 71930-0066-12 Eywa 100 tablets $0.068 AB Availability likely —
Baclofen 5 mg 72888-0009-01 Advagen 100 tablets $0.068 AB Availability likely —
Baclofen 5 mg 00615-8518-05 NCS 15 tablets — AB FDA listed —
Baclofen 5 mg 42571-0427-01 Micro 100 tablets — AB Discontinued —
Baclofen 5 mg 51407-0972-01 Golden 100 tablets — AB FDA listed —
Baclofen 5 mg 55154-4349-00 Cardinal 10 tablets — AB FDA listed —
Baclofen 5 mg 70518-4656-00 REMEDYREPACK 14 tablets — AB FDA listed —
Baclofen 5 mg 70771-1586-01 Zydus 100 tablets — AB FDA listed —
Baclofen 5 mg 71335-3050-01 Bryant 30 tablets — AB FDA listed —
Baclofen 5 mg 71335-3051-01 Bryant 30 tablets — AB FDA listed —
Baclofen 5 mg 72162-2372-01 Bryant 100 tablets — AB FDA listed —
Baclofen 5 mg 72162-2448-01 Bryant 100 tablets — AB FDA listed —
Baclofen 5 mg 72789-0478-01 PD-Rx 100 tablets — AB FDA listed —
Baclofen 5 mg 72865-0296-01 XLCare 100 tablets — AB FDA listed —
Baclofen 5 mg 76420-0356-01 Asclemed 100 tablets — AB FDA listed —
Baclofen 5 mg 82804-0219-90 Proficient 90 tablets — AB FDA listed —
Baclofen 5 mg 84386-0035-93 Aurobindo 9000 tablets — AB FDA listed —
About this product: this is a generic version of the medicine. FDA equivalence ratings are shown when available, and other versions are listed above, least expensive first.
Where does this data come from?
Equivalents are other NDCs of the same ingredient, form and route from the openFDA NDC Directory, ranked least-expensive-first by NADAC. Therapeutic-equivalence (AB) ratings come from the FDA Orange Book; biologics use the FDA Purple Book for biosimilar & interchangeable status.

Availability & generic status

🏛️
2022
On the market since
Jan 2022
📍
2026
Currently FDA-listed
4 years listed
🔓
·
Generic on the market
this product is a generic
✅This is a generic drug

This product is an FDA-approved generic. Other versions of the same drug are listed under Therapeutic equivalents, least expensive first.

Where does this data come from?
Patents and exclusivity from the FDA Orange Book (small-molecule drugs), refreshed from public FDA data. Generic launch timing is an estimate, not a guarantee.

What it looks like

Color White
ShapeRound
ImprintLS;289
Size11 mm
ScoringScored — splits in 2
One label can cover several strengths, so colors may be combined — always confirm a loose pill against the dispensed prescription label or a pharmacist.
Where does this data come from?
Physical description (imprint, shape, color, scoring, coating) from this product’s FDA Structured Product Labeling (SPL), mirrored from DailyMed / openFDA.

Inactive Ingredients / Excipients

Inactive ingredients, also called excipients, are components of the drug product other than the active ingredient. They may include fillers, dyes, coatings, preservatives, flavors, or other formulation ingredients.

💡 Tap an ingredient (hover on desktop) to see what it is and why it’s used.

  • UNII 3SY5LH9PMK
    Anhydrous lactose is a milk sugar with no water content. It acts as a filler and binder in tablets and capsules, adding bulk and helping ingredients stick together.
  • UNII OP1R32D61U
    Microcrystalline cellulose is a purified form of cellulose, a natural fiber from plant sources. It acts as a binder and filler in tablets and capsules, helping hold ingredients together and give the medicine its shape and size.
  • UNII O7TSZ97GEP
    A mineral compound that serves as a filler and binding agent in tablets and capsules. It adds bulk to the medicine and helps hold ingredients together during manufacturing.
  • UNII 70097M6I30
    Magnesium stearate is a salt made from magnesium and stearic acid, a fatty substance. It's used in tablets and capsules as a lubricant and glidant to help ingredients flow smoothly during manufacturing and prevent sticking.
  • UNII ETJ7Z6XBU4
    Silicon dioxide is a naturally occurring mineral used as a glidant and anti-caking agent. It helps powder ingredients flow smoothly and prevents clumping during manufacturing and storage.
  • UNII H8AV0SQX4D
    A modified starch derived from potato or corn starch. It absorbs water quickly and helps tablets or capsules break apart and dissolve in the stomach, acting as a disintegrant to ensure the medicine releases its active ingredients properly.

6 inactive ingredients listed in the exact product block matched to this NDC.

Where does this data come from?
Data sourced from official FDA Structured Product Labeling (SPL) via DailyMed — ingredient classCode="IACT" elements from the exact product block matched by this NDC. Label-section narrative from DailyMed / the openFDA label index is shown separately when available.

Inactive ingredient FAQ

Are inactive ingredients the same for every manufacturer?
No. Inactive ingredients can differ by manufacturer, dosage form, strength, and package / product version.
Why might an inactive ingredient be missing?
Some SPLs do not provide a complete structured inactive-ingredient list, and older or unusual labels may only include the information in narrative text.
Can inactive ingredients matter?
Yes. They can matter for allergies, intolerances, dyes, gluten / lactose concerns, preservatives, and formulation differences — but confirm with a pharmacist or the manufacturer when it’s clinically important.

Manufacturer & labeler

LabelerLifestar Pharma LLC
Application holderMANKIND PHARMA LTD
FDA applicationANDA215885 (ANDA)
Labeler code70756
First marketedJan 2022
Product typeHuman Prescription Drug
Portfolio155 products on file
The labeler markets the product; the application holder owns the FDA approval. They’re often the same company but can differ (e.g. a repackager or an authorized generic). A mailing address / phone appears here when the manufacturer includes it in the product’s FDA label (not all do).
Where does this data come from?
Labeler, application holder and registered establishment from the FDA openFDA NDC Directory and Drugs@FDA; address/contact from the product’s FDA label.

Full prescribing information FDA SPL

The complete FDA label for this product — the official prescribing information, verbatim, section by section. Jump with a chip, search within the label, or expand everything.
🎯 Indications and Usage 108 words ▾

INDICATIONS AND USAGE Baclofen tablets are useful for the alleviation of signs and symptoms of spasticity resulting from multiple sclerosis, particularly for the relief of flexor spasms and concomitant pain, clonus, and muscular rigidity. Patients should have reversible spasticity so that baclofen treatment will aid in restoring residual function. Baclofen tablets may also be of some value in patients with spinal cord injuries and other spinal cord diseases.

Baclofen tablets are not indicated in the treatment of skeletal muscle spasm resulting from rheumatic disorders. The efficacy of baclofen in stroke, cerebral palsy, and Parkinson's disease has not been established and, therefore, it is not recommended for these conditions.

⏱️ Dosage and Administration 121 words ▾

DOSAGE AND ADMINISTRATION The determination of optimal dosage requires individual titration. Start therapy at a low dosage and increase gradually until optimum effect is achieved (usually between 40 to 80 mg daily). The following dosage titration schedule is suggested: 5 mg t.i.d. for 3 days 10 mg t.i.d. for 3 days 15 mg t.i.d. for 3 days 20 mg t.i.d. for 3 days Thereafter additional increases may be necessary but the total daily dose should not exceed a maximum of 80 mg daily (20 mg q.i.d.).

The lowest dose compatible with an optimal response is recommended. If benefits are not evident after a reasonable trial period, patients should be slowly withdrawn from the drug (see WARNINGS , Abrupt Drug Withdrawal ).

⛔ Contraindications 4 words ▾

CONTRAINDICATIONS Hypersensitivity to baclofen.

⚠️ Warnings ~2 min read ▾

WARNINGS a. Neonatal Withdrawal Symptoms : Withdrawal symptoms have been reported starting hours to days after delivery in neonates whose mothers were treated with oral baclofen throughout pregnancy. The symptoms of withdrawal in these infants have included increased muscle tone, tremor, jitteriness, and seizure.

If the potential benefit justifies the potential risk to the fetus and oral baclofen is continued during pregnancy, gradually reduce the dose and discontinue baclofen before delivery. If slow withdrawal is not feasible, advise the parents or caregivers of the potential for neonatal withdrawal. b. Abrupt Drug Withdrawal : Hallucinations and seizures have occurred on abrupt withdrawal of baclofen.

Therefore, except for serious adverse reactions, the dose should be reduced slowly when the drug is discontinued. c. Impaired Renal Function : Because baclofen is primarily excreted unchanged through the kidneys, it should be given with caution, and it may be necessary to reduce the dosage. d. Stroke : Baclofen has not significantly benefited patients with stroke.

These patients have also shown poor tolerability to the drug. e. Pregnancy : Baclofen has been shown to increase the incidence of omphaloceles (ventral hernias) in fetuses of rats given approximately 13 times the maximum dose recommended for human use, at a dose which caused significant reductions in food intake and weight gain in dams. This abnormality was not seen in mice or rabbits.

There was also an increased incidence of incomplete sternebral ossification in fetuses of rats given approximately 13 times the maximum recommended human dose, and an increased incidence of unossified phalangeal nuclei of forelimbs and hindlimbs in fetuses of rabbits given approximately 7 times the maximum recommended human dose. In mice, no teratogenic effects were observed, although reductions in mean fetal weight with consequent delays in skeletal ossification were present when dams were given 17 and 34 times the human daily dose.

There are no studies in pregnant women. Baclofen should be used during pregnancy only if the benefit clearly justifies the potential risk to the fetus.

🤒 Adverse Reactions ~1 min read ▾

ADVERSE REACTIONS The most common is transient drowsiness (10 to 63%). In one controlled study of 175 patients, transient drowsiness was observed in 63% of those receiving baclofen compared to 36% of those in the placebo group. Other common adverse reactions are dizziness (5 to 15%), weakness (5 to 15%) and fatigue (2 to 4%).

Others reported: Neuropsychiatric: Confusion (1 to 11%), headache (4 to 8%), insomnia (2 to 7%); and, rarely, euphoria, excitement, depression, hallucinations, paresthesia, muscle pain, tinnitus, slurred speech, coordination disorder, tremor, rigidity, dystonia, ataxia, blurred vision, nystagmus, strabismus, miosis, mydriasis, diplopia, dysarthria, epileptic seizure. Cardiovascular: Hypotension (0 to 9%). Rare instances of dyspnea, palpitation, chest pain, syncope.

Gastrointestinal: Nausea (4 to 12%), constipation (2 to 6%); and rarely, dry mouth, anorexia, taste disorder, abdominal pain, vomiting, diarrhea, and positive test for occult blood in stool. Genitourinary: Urinary frequency (2 to 6%); and rarely, enuresis, urinary retention, dysuria, impotence, inability to ejaculate, nocturia, hematuria. Other: Instances of rash, pruritus, ankle edema, excessive perspiration, weight gain, nasal congestion.

Some of the CNS and genitourinary symptoms may be related to the underlying disease rather than to drug therapy. The following laboratory tests have been found to be abnormal in a few patients receiving baclofen: increased SGOT, elevated alkaline phosphatase, and elevation of blood sugar. To report SUSPECTED ADVERSE REACTIONS, contact Lifestar Pharma LLC at 1-888-995-4337 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

🧒 Pediatric Use 18 words ▾

Pediatric Use Safety and effectiveness in pediatric patients below the age of 12 years have not been established.

🆘 Overdosage 58 words ▾

OVERDOSAGE Signs and Symptoms: Vomiting, muscular hypotonia, drowsiness, accommodation disorders, coma, respiratory depression and seizures. Treatment: In the alert patient, empty the stomach promptly by induced emesis followed by lavage. In the obtunded patient, secure the airway with a cuffed endotracheal tube before beginning lavage (do not induce emesis). Maintain adequate respiratory exchange, do not use respiratory stimulants.

🧬 Clinical Pharmacology 147 words ▾

CLINICAL PHARMACOLOGY The precise mechanism of action of baclofen is not fully known. Baclofen is capable of inhibiting both monosynaptic and polysynaptic reflexes at the spinal level, possibly by hyperpolarization of afferent terminals, although actions at supraspinal sites may also occur and contribute to its clinical effect. Although baclofen is an analog of the putative inhibitory neurotransmitter gamma-aminobutyric acid (GABA), there is no conclusive evidence that actions on GABA systems are involved in the production of its clinical effects.

In studies with animals baclofen has been shown to have general CNS depressant properties as indicated by the production of sedation with tolerance, somnolence, ataxia, and respiratory and cardiovascular depression. Baclofen is rapidly and extensively absorbed and eliminated. Absorption may be dose-dependent, being reduced with increasing doses.

Baclofen is excreted primarily by the kidney in unchanged form and there is relatively large intersubject variation in absorption and/or elimination.

📦 How Supplied / Storage and Handling ~1 min read ▾

HOW SUPPLIED Baclofen Tablets USP, 5 mg are available as a white to off white, round, flat-faced, beveled edge tablet, debossed with "LS" on one side and "85" on the other side, containing 5 mg baclofen, USP are supplied as follows: Bottle of 100 tablets, with child-resistant closure. NDC 70756-085-11 Baclofen Tablets USP, 10 mg are available as a white to off white, round, flat-faced, beveled edge tablet, debossed with "LS 288" on one side and functional scored on the other side, containing 10 mg baclofen, USP are supplied as follows: Bottle of 100 tablets, with child-resistant closure.

NDC 70756-288-11 Bottle of 1000 tablets. This package is not child resistant. NDC 70756-288-12 Unit-dose child-resistant blister pack of 100 (10 x 10) tablets.

NDC 70756-288-99 NDC 70756-288-12 in bottle of 1000 tablets. This package is not child resistant. Baclofen Tablets USP, 20 mg are available as a white to off white, round, flat-faced, beveled edge tablet debossed with "LS 289" on one side and functional scored on the other side, containing 20 mg baclofen, USP are supplied as follows: Bottle of 100 tablets, with child-resistant closure.

NDC 70756-289-11 Bottle of 500 tablets. This package is not child resistant. NDC 70756-289-51 Bottle of 1000 tablets.

This package is not child resistant. NDC 70756-289-12 Unit-dose child-resistant blister pack of 100 (10 x 10) tablets. NDC 70756-289-99 Dispense in a well-closed container as defined in the USP, with a child-resistant closure.

Store at 20° to 25°C [68° to 77°F] [See USP Controlled Room Temperature]. KEEP THIS AND ALL MEDICATIONS OUT OF THE REACH OF CHILDREN. Manufactured for: Lifestar Pharma LLC 1200 MacArthur Blvd.

Mahwah, NJ 07430 USA Product of Poland or Manufactured for: Lifestar Pharma LLC 1200 MacArthur Blvd. Mahwah, NJ 07430 USA Made in India Revised: October 2023, V-05

📋 Description 98 words ▾

DESCRIPTION Baclofen, USP is a muscle relaxant and antispastic. Its chemical name is 4-amino-3-(4-chlorophenyl)-butanoic acid. The structural formula is: C 10 H 12 ClNO 2 M.W.

213.66 Baclofen, USP is a white to off-white odorless or practically odorless crystalline powder. It is slightly soluble in water, very slightly soluble in methanol and insoluble in chloroform. Each tablet, for oral administration, contains 5 mg, 10 mg or 20 mg baclofen, USP.

In addition, each tablet contains the following inactive ingredients: anhydrous lactose, colloidal silicon dioxide, dibasic calcium phosphate dihydrate, magnesium stearate, microcrystalline cellulose and sodium starch glycolate. Structural Formula

⚠️ Precautions ~1 min read ▾

PRECAUTIONS Because of the possibility of sedation, patients should be cautioned regarding the operation of automobiles or other dangerous machinery, and activities made hazardous by decreased alertness. Patients should also be cautioned that the central nervous system effects of baclofen may be additive to those of alcohol and other CNS depressants. Baclofen should be used with caution where spasticity is utilized to sustain upright posture and balance in locomotion or whenever spasticity is utilized to obtain increased function.

In patients with epilepsy, the clinical state and electroencephalogram should be monitored at regular intervals, since deterioration in seizure control and EEG have been reported occasionally in patients taking baclofen. It is not known whether this drug is excreted in human milk. As a general rule, nursing should not be undertaken while a patient is on a drug since many drugs are excreted in human milk.

A dose-related increase in incidence of ovarian cysts and a less marked increase in enlarged and/or hemorrhagic adrenal glands was observed in female rats treated chronically with baclofen. Ovarian cysts have been found by palpation in about 4% of the multiple sclerosis patients that were treated with baclofen for up to one year. In most cases these cysts disappeared spontaneously while patients continued to receive the drug.

Ovarian cysts are estimated to occur spontaneously in approximately 1% to 5% of the normal female population. Pediatric Use Safety and effectiveness in pediatric patients below the age of 12 years have not been established.

📄 Package Label / Principal Display Panel ~2 min read ▾

NDC 70756-085-11 Baclofen Tablets, USP 5 mg Rx only 100 TABLETS Product of Poland NDC 70756-085-11 Baclofen Tablets, USP 5 mg Rx only 100 TABLETS Made in India Baclofen Tablets USP 5 mg 100s Label 5 mg 100 lablets

NDC 70756-288-11 Baclofen Tablets, USP 10 mg Rx only 100 TABLETS Product of Poland NDC 70756-288-11 Baclofen Tablets, USP 10 mg Rx only 100 TABLETS Made in India NDC 70756-288-12 Baclofen Tablets, USP 10 mg Rx only 1000 Tablets Product of Poland NDC 70756-288-12 Baclofen Tablets, USP 10 mg Rx only 1000 Tablets Made in India NDC 70756-289-11 Baclofen Tablets, USP 20 mg Rx only 100 Tablets Product of Poland NDC 70756-289-11 Baclofen Tablets, USP 20 mg Rx only 100 Tablets Made in India NDC 70756-289-51 Baclofen Tablets, USP 20 mg Rx only 500 Tablets Product of Poland NDC 70756-289-51 Baclofen Tablets, USP 20 mg Rx only 500 Tablets Made in India NDC 70756-289-12 Baclofen Tablets, USP 20 mg Rx only 1000 Tablets Product of Poland NDC 70756-289-12 Baclofen Tablets, USP 20 mg Rx only 1000 Tablets Made in India NDC 70756-288-01 Baclofen Tablet, USP 10 mg Rx only 10 tablets Product of Poland NDC 70756-288-01 Baclofen Tablet, USP 10 mg Rx only 10 tablets Made in India NDC 70756-288-99 Baclofen Tablets, USP 10 mg per tablet Rx only 100 Tablets Product of Poland NDC 70756-288-99 Baclofen Tablets, USP 10 mg per tablet Rx only 100 Tablets Made in India NDC 70756-289-01 Baclofen Tablet, USP 20 mg Rx only 10 Tablets Product of Poland NDC 70756-289-01 Baclofen Tablet, USP 20 mg Rx only 10 Tablets Made in India NDC 70756-289-99 Baclofen Tablets, USP 20 mg per tablet Rx only 100 Tablets Product of Poland NDC 70756-289-99 Baclofen Tablets, USP 20 mg per tablet Rx only 100 Tablets Made in India Baclofen Tablets USP 10 mg 100s Label 10 mg 100 tablets Baclofen Tablets USP 10 mg 1000s Label 100 mg 1000 tablets Baclofen Tablets USP 20 mg 100s Label 20 mg 100 tablets Baclofen Tablets USP 20 mg 500s Label 20 mg 500 tablets Baclofen Tablets USP 20 mg 1000s Label 20 mg 1000 tablets 10's blister 10 mg blister Carton 10 mg- 10 x 10's blister 10 mg carton 10's blister - 20 mg 20 mg blister Carton 20 mg - 10 x 10's blister 20 mg carton

Source: FDA Structured Product Labeling, mirrored from DailyMed / openFDA. Prefer the government’s original formatting? View this label on DailyMed ↗

Medicaid utilization & spend

📍 This exact package only: Medicaid data is reported per full 11-digit NDC — labeler, product and pack size — so every number here is for this package alone, not the drug overall. Other pack sizes report separately.
💊 Pharmacy benefit only: These are Medicaid outpatient pharmacy claims, billed by NDC. They exclude the medical benefit — clinic- or hospital-administered drugs billed under HCPCS J-codes — so drugs used mostly that way (e.g. Avastin, Lucentis, Keytruda) can look low or missing here. That’s expected, not an error.
📅 Q1 2025 – Q1 2026 · 5 quarters of data
ⓘ The newest quarter is usually incomplete when first published; states restate recent quarters in later CMS releases, so the latest figures typically revise upward. State coverage-policy changes can also shift quarter-to-quarter totals.
Prescriptions last 4 qtrs
52.8K
Units reimbursed last 4 qtrs
3.8M
Gross reimbursed last 4 qtrs
$875.5K
Avg / prescription
$16.57
Avg / unit
$0.2298
Latest quarter Q1 2026
13.6KRx
Medicaid pays / ea
$0.2298
gross reimbursed
vs
NADAC / ea
$0.0680
acquisition cost
=
Spread
+$0.1618
+238% vs cost
What Medicaid paid per ea (before rebates; includes the pharmacy’s dispensing fee) compared with NADAC — the average price pharmacies pay to buy the drug. A positive spread means Medicaid reimbursed more than the purchase price, before manufacturer rebates.
Fee-for-service vs managed care ⓘ
55% FFS 45% MCO
Fee-for-service · 28,992 Rx Managed care · 23,854 Rx
State Medicaid map
Alaska: 9,018 units · 1,230 per 100k residents AK Maine: 29,827 units · 2,138 per 100k residents ME Washington: 109,241 units · 1,398 per 100k residents WA Idaho: 11,973 units · 610 per 100k residents ID Montana: 21,912 units · 1,936 per 100k residents MT North Dakota: no data reported ND Minnesota: 14,368 units · 250 per 100k residents MN Wisconsin: 39,769 units · 673 per 100k residents WI Michigan: 17,600 units · 175 per 100k residents MI New York: 80,422 units · 411 per 100k residents NY Vermont: 5,885 units · 910 per 100k residents VT New Hampshire: 8,560 units · 611 per 100k residents NH Oregon: 43,439 units · 1,026 per 100k residents OR Nevada: 70,524 units · 2,208 per 100k residents NV Wyoming: 3,040 units · 521 per 100k residents WY South Dakota: 2,994 units · 326 per 100k residents SD Iowa: 6,813 units · 212 per 100k residents IA Illinois: 37,672 units · 300 per 100k residents IL Indiana: 50,129 units · 731 per 100k residents IN Ohio: 66,274 units · 562 per 100k residents OH Pennsylvania: 40,134 units · 310 per 100k residents PA New Jersey: 2,610 units · 28.1 per 100k residents NJ Massachusetts: 357,482 units · 5,106 per 100k residents MA California: 1,155,587 units · 2,966 per 100k residents CA Utah: 7,316 units · 214 per 100k residents UT Colorado: 27,398 units · 466 per 100k residents CO Nebraska: 10,262 units · 519 per 100k residents NE Missouri: 59,791 units · 965 per 100k residents MO Kentucky: 45,594 units · 1,007 per 100k residents KY West Virginia: 5,777 units · 326 per 100k residents WV Virginia: 215,051 units · 2,467 per 100k residents VA Maryland: 80,437 units · 1,302 per 100k residents MD Connecticut: 126,985 units · 3,511 per 100k residents CT Rhode Island: 45,204 units · 4,128 per 100k residents RI Arizona: 76,701 units · 1,032 per 100k residents AZ New Mexico: no data reported NM Kansas: 9,621 units · 327 per 100k residents KS Arkansas: 13,773 units · 449 per 100k residents AR Tennessee: 28,454 units · 399 per 100k residents TN North Carolina: 178,574 units · 1,648 per 100k residents NC South Carolina: 70,393 units · 1,310 per 100k residents SC Delaware: 1,244 units · 121 per 100k residents DE Oklahoma: no data reported OK Louisiana: 27,855 units · 609 per 100k residents LA Mississippi: 19,773 units · 673 per 100k residents MS Alabama: 65,102 units · 1,275 per 100k residents AL Georgia: 8,590 units · 77.9 per 100k residents GA D.C.: 9,304 units · 1,370 per 100k residents DC Hawaii: 26,581 units · 1,852 per 100k residents HI Texas: 177,358 units · 581 per 100k residents TX Florida: 287,098 units · 1,270 per 100k residents FL
Units reimbursed · per 100k residents
28.15,106
gray = no data reported ⓘ
Colors are per 100,000 residents, so big states don’t automatically dominate. Tap or hover a state for its actual totals.
Tap or hover a state
…for its Medicaid breakdown
🏆 Top states by units · per 100k residents
1 Massachusetts 5,106 /100k
2 Rhode Island 4,128 /100k
3 Connecticut 3,511 /100k
4 California 2,966 /100k
5 Virginia 2,467 /100k
6 Nevada 2,208 /100k
7 Maine 2,138 /100k
8 Montana 1,936 /100k
National units — by quarter
💵 About the dollar figures: “reimbursed” is what Medicaid paid pharmacies before confidential manufacturer rebates, so the program’s real net cost is lower than these numbers. Fee-for-service and managed-care claims are combined unless split above. Source: CMS State Drug Utilization Data; per-100k rates use 2023 Census population estimates.

Medicare Part D spend CMS · PART D · 2026 (Q1)

Medicare Part D (outpatient prescription) spending for Baclofen — the program that covers self-administered drugs. 23 manufacturers.
⚠️ Drug-level data: CMS publishes Part D spending by drug, not by NDC — these figures combine every manufacturer, strength and package size sold under the name Baclofen. That’s a different level of aggregation than the Medicaid card above, which is specific to this exact 11-digit NDC (pack size included), so the two aren’t directly comparable.
Period
Total Part D spend
$22.67M
Claims incl. refills
1.3M
Beneficiaries
744.4K
Spend / beneficiary
$30.45
Spend / claim
$17.31
Trend by period
💵 About the dollar figures: spending is what Part D plans paid before confidential manufacturer rebates, so the program’s real net cost is lower. A blank patient count means fewer than 11 people — CMS hides counts that small to protect privacy. Source: CMS Medicare Quarterly Part D Spending by Drug (data.cms.gov), updated quarterly.
For educational and professional reference only — not medical advice. Pricing reflects published NADAC and CMS ASP (free public data) and may differ from your acquisition cost; always verify before billing or dispensing.